Table 2.

Base case cost-effectiveness results from genetic screening for POAG compared to current practice.

	Lifetime costs per person, Local currency	QALYs per person	Incremental costs per person, Local currency (95% CI)	Incremental QALYs per person (95% CI)	QALY ICERs, Local currency (95% CI)	Years of blindness per person	Years of blindness avoided per person	Blindness ICERs, Local currency (95% CI)
Australia
Current POAG practice	53,943	12.794	–	–	–	0.392	–	–
Genetic screening	54,424	12.808	574 (402–741)	0.014 (0.006–0.024)	34,252 (21,324–95,497)	0.356	0.036 (0.015–0.063)	13,359 (8143–37,448)
United Kingdom
Current POAG practice	36,489	13.156	–	–	–	0.272	–	–
Genetic screening	37,127	13.167	278 (221–389)	0.0112 (0.005–0.020)	24,783 (13,373–66,960)	0.244	0.028 (0.011–0.049)	10,095 (5513–27,656)

Local currency is Australian dollars for Australia and Great British Pounds for the United Kingdom. Costs, QALYs, and Years of Blindness are discounted lifetime totals per person. ICERs are calculated by comparing the Genetic Screening to the Current POAG practice. Given values are based on the expected values for the variables, whilst the 95% confidence intervals are derived from the Monte Carlo analysis.

QALY quality adjusted life year, ICER incremental cost effectiveness ratio, POAG primary open angle glaucoma